Home » Stocks » VBIV

VBI Vaccines, Inc. (VBIV)

Stock Price: $2.63 USD -0.09 (-3.14%)
Updated Apr 19, 2021 11:47 AM EDT - Market open
Market Cap 688.35M
Revenue (ttm) 1.06M
Net Income (ttm) -46.23M
Shares Out 254.00M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $2.63
Previous Close $2.71
Change ($) -0.09
Change (%) -3.14%
Day's Open 2.71
Day's Range 2.62 - 2.81
Day's Volume 1,853,291
52-Week Range 1.02 - 6.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announce...

1 month ago - Business Wire

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Other stocks mentioned: AIM, ASXC, CLSN, IBIO, JAGX, OVID, RIGL
1 month ago - InvestorPlace

The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candid...

1 month ago - Benzinga

VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.

1 month ago - Zacks Investment Research

OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. (Nasdaq: VBIV), today announced a partnership to develop VBI'...

1 month ago - Business Wire

VBI Vaccines Inc (NASDAQ: VBIV) initiates enrollment in Phase 1/2 study of VBI-2902, its monovalent enveloped virus-like particle (eVLP), COVID-19 vaccine candidate. The adaptive 60-subject study will e...

1 month ago - Benzinga

OTTAWA, Ontario--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today...

1 month ago - Business Wire

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, toda...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

2 months ago - Business Wire

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's k...

Other stocks mentioned: CLVS, DVAX, LCI, NAKD, OPK, PGEN, SENS ...
2 months ago - Benzinga

VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

2 months ago - Business Wire

Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings is ...

Other stocks mentioned: ESPR, NVS
3 months ago - Benzinga

The company reported good news from a study of its hepatitis B vaccine.

3 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

3 months ago - Business Wire

With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GNUS) Hertz ...

Other stocks mentioned: CHKAQ, GNUS, HTZGQ, MARK, OCGN, STON, XSPA
3 months ago - InvestorPlace

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

3 months ago - Business Wire

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-oncology vac...

Other stocks mentioned: SYNH
4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

4 months ago - Business Wire

VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacci...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: APTX, SELB
5 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

5 months ago - Business Wire

Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.

Other stocks mentioned: SRNE, VXRT
5 months ago - The Motley Fool

Neither biotech is in the front of the pack in developing a COVID-19 vaccine.

Other stocks mentioned: INO
6 months ago - The Motley Fool

It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.

Other stocks mentioned: AMWL, BABA, GME, IFRX, SNE, SWBI
6 months ago - InvestorPlace

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

6 months ago - Business Wire

In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.95, marking a +0.68% move from the previous day.

6 months ago - Zacks Investment Research

In the race for a vaccine, a pause in progress sets you back.

Other stocks mentioned: ALT, CVAC
6 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

6 months ago - Business Wire

In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.98, marking a +0.68% move from the previous day.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccin...

6 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) closed the most recent trading day at $3.76, making no change from the previous trading session.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

7 months ago - Business Wire

The biotech will present additional data for one of its pipeline candidates later this week.

7 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

7 months ago - Business Wire

VBI Vaccines, Inc. (VBIV) closed at $3.12 in the latest trading session, marking a +0.65% move from the prior day.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

7 months ago - Business Wire

Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.

7 months ago - The Motley Fool

About VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP progr... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
VBIV
Full Company Profile

Financial Performance

In 2020, VBI Vaccines's revenue was $1.06 million, a decrease of -52.23% compared to the previous year's $2.22 million. Losses were -$46.23 million, -15.66% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 7.50, which is an increase of 185.71% from the latest price.

Price Target
$7.50
(185.71% upside)
Analyst Consensus: Strong Buy